Quick Access

No journals followed

Browse journals

No saved papers

Feed Explore Journal Club Trending Questions Researchers

⌘K

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes | Synapse

October 23, 2020Open Access

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Key Points

This research aims to assess the effects of finerenone on chronic kidney disease (CKD) outcomes in patients with type 2 diabetes.
Randomized trial designed to compare finerenone against a placebo
Included patients diagnosed with chronic kidney disease and type 2 diabetes
Clinical outcome measures focused on CKD progression and cardiovascular events
Finerenone significantly reduced the risk of CKD progression compared to placebo (exact metrics not provided)
Finerenone also lowered the risk of cardiovascular events relative to those given placebo

Abstract

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Authors

G

George L. Bakris

R

Rajiv Agarwal

S

Stefan D. Anker

Journals

New England Journal of Medicine

Actions

Institutions

University of Michigan

University of Chicago

University of Copenhagen

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Cite this study

Bakris et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69aed521e0fc378064e706ed — DOI: https://doi.org/10.1056/nejmoa2025845